Craniopharyngioma diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(9 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Craniopharyngioma}}
{{Craniopharyngioma}}
{{CMG}}; {{AE}}
{{CMG}}{{AE}}{{Marjan}}
== Overview ==
== Overview ==
The diagnostic evaluation of craniopharyngioma includes high-definition brain imaging. Brain MRI with and without contrast is the gold standard. Computed tomography (CT) scan is optional and may show some calcifications that can be seen in these tumors. However CT is not specific enough as a standalone diagnostic test. vascular imaging studies such as MR angiography (MRA) or CTA, is decided on a case-by-case basis typically for surgical planning or if a possible vascular malformation is spuspected.
The [[Diagnosis|diagnostic evaluation]] of craniopharyngioma includes [[MRI|high-definition brain imaging]]. [[Magnetic resonance imaging|Brain MRI]] [[Magnetic resonance imaging|with and without contrast]] is the [[Gold standard (test)|gold standard]]. [[Computed tomography|Computed tomography (CT) scan]] is optional and may show some [[Calcification|calcifications]] that can be seen in these [[Tumor|tumors]]. However [[Computed tomography|CT]] is not specific enough as a stand alone [[diagnostic test]]. [[Magnetic resonance angiography|Vascular imaging]] studies such as [[Magnetic resonance angiography|MR angiography (MRA)]] or [[CT angiography|CTA]] is decided on a case-by-case basis typically for [[Surgery|surgical planning]] or if a possible [[vascular malformation]] is suspected.


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==
 
*Craniopharyngiomas have the most [[Craniopharyngioma CT|heterogeneous radiologic appearance]] of any [[Pituitary gland|suprasellar neoplasm]].<ref name="pmid28155902">{{cite journal |vauthors=Müller HL, Merchant TE, Puget S, Martinez-Barbera JP |title=New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma |journal=Nat Rev Endocrinol |volume=13 |issue=5 |pages=299–312 |date=May 2017 |pmid=28155902 |doi=10.1038/nrendo.2016.217 |url=}}</ref>
*Craniopharyngioma can offer a challenge in arriving at the correct [[diagnosis]]. 
*The [[Rathke's pouch|radiologic characteristics of Rathke cleft cyst]] can overlap that of adamantinomatous craniopharyngioma.<ref name="pmid27258775">{{cite journal |vauthors=Cohen LE |title=Update on childhood craniopharyngiomas |journal=Curr Opin Endocrinol Diabetes Obes |volume=23 |issue=4 |pages=339–44 |date=August 2016 |pmid=27258775 |doi=10.1097/MED.0000000000000264 |url=}}</ref> 
*
=== Study of choice ===
=== Study of choice ===
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The following result of [gold standard test] is confirmatory of [disease name]:
* [Result 1]
* [Result 2]
OR
[Name of the investigation] must be performed when:
* The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
* A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
OR
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The diagnostic study of choice for [disease name] is [name of the investigation].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
OR
[Disease name] is primarily diagnosed based on the clinical presentation.
OR
Investigations:
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
==== The comparison of various diagnostic studies for [disease name] ====
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Test
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Sensitivity
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specificity
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 1
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 2
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|}
<small> [Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity</small>
===== Diagnostic results =====
The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:
* [Finding 1]
* [Finding 2]
===== Sequence of Diagnostic Studies =====
The [name of investigation] must be performed when:
* The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
* A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
* [Initial investigation]
* [2nd investigation]
=== Name of Diagnostic Criteria ===
'''It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.'''
[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
OR
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:
* Criteria 1
* Criteria 2
* Criteria 3
OR
'''IF there are clear, established diagnostic criteria'''
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
'''IF there are no established diagnostic criteria'''


There are no established criteria for the diagnosis of [disease name].
*[[Magnetic resonance imaging|Pre and post contrast enhanced MR imaging]] with attention to the [[Sella turcica|sellar region]] is the [[Modality|modality of choice]] when evaluating craniopharyngioma.<ref name="pmid27903124">{{cite journal |vauthors=Martinez-Gutierrez JC, D'Andrea MR, Cahill DP, Santagata S, Barker FG, Brastianos PK |title=Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy |journal=Neurosurg Focus |volume=41 |issue=6 |pages=E2 |date=December 2016 |pmid=27903124 |doi=10.3171/2016.9.FOCUS16325 |url=}}</ref>
*The [[Magnetic resonance imaging|superior resolution and tissue characterization]], as well as the [[Magnetic resonance imaging|multiplanar capability of MRI]] make it the [[Radiology|radiologist’s]] indispensable tool.
*[[Computed tomography|High-resolution]], [[Craniopharyngioma MRI|thin-section, T1-weighted imaging of the sellar region]] in the [[Anatomical terms of location|sagittal and coronal planes]] is mandatory, and should be obtained both [[Magnetic resonance imaging|pre- and post-contrast administration]].<ref name="pmid28838874">{{cite journal |vauthors=Patel VS, Thamboo A, Quon J, Nayak JV, Hwang PH, Edwards M, Patel ZM |title=Outcomes After Endoscopic Endonasal Resection of Craniopharyngiomas in the Pediatric Population |journal=World Neurosurg |volume=108 |issue= |pages=6–14 |date=December 2017 |pmid=28838874 |doi=10.1016/j.wneu.2017.08.058 |url=}}</ref>
*[[Craniopharyngioma MRI|Dynamic enhanced imaging of the sellar region]] can be performed if diagnostic considerations include [[Pituitary adenoma|pituitary microadenoma]] or the rare [[Hemangioma|parasellar cavernous hemangioma]].
*[[Computed tomography|CT]] is also sensitive in the detection of fat density which is valuable in the [[Sella turcica|suprasellar region]] when the differential include [[Rathke's pouch|Rathke cleft cyst]].<ref name="pmid24467716">{{cite journal |vauthors=Müller HL |title=Craniopharyngioma |journal=Endocr. Rev. |volume=35 |issue=3 |pages=513–43 |date=June 2014 |pmid=24467716 |doi=10.1210/er.2013-1115 |url=}}</ref>


==References==
==References==

Latest revision as of 15:26, 26 February 2019

Craniopharyngioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Craniopharyngioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Craniopharyngioma diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Craniopharyngioma diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Craniopharyngioma diagnostic study of choice

CDC on Craniopharyngioma diagnostic study of choice

Craniopharyngioma diagnostic study of choice in the news

Blogs on Craniopharyngioma diagnostic study of choice

Directions to Hospitals Treating Craniopharyngioma

Risk calculators and risk factors for Craniopharyngioma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

The diagnostic evaluation of craniopharyngioma includes high-definition brain imaging. Brain MRI with and without contrast is the gold standard. Computed tomography (CT) scan is optional and may show some calcifications that can be seen in these tumors. However CT is not specific enough as a stand alone diagnostic test. Vascular imaging studies such as MR angiography (MRA) or CTA is decided on a case-by-case basis typically for surgical planning or if a possible vascular malformation is suspected.

Diagnostic Study of Choice

Study of choice

References

  1. Müller HL, Merchant TE, Puget S, Martinez-Barbera JP (May 2017). "New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma". Nat Rev Endocrinol. 13 (5): 299–312. doi:10.1038/nrendo.2016.217. PMID 28155902.
  2. Cohen LE (August 2016). "Update on childhood craniopharyngiomas". Curr Opin Endocrinol Diabetes Obes. 23 (4): 339–44. doi:10.1097/MED.0000000000000264. PMID 27258775.
  3. Martinez-Gutierrez JC, D'Andrea MR, Cahill DP, Santagata S, Barker FG, Brastianos PK (December 2016). "Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy". Neurosurg Focus. 41 (6): E2. doi:10.3171/2016.9.FOCUS16325. PMID 27903124.
  4. Patel VS, Thamboo A, Quon J, Nayak JV, Hwang PH, Edwards M, Patel ZM (December 2017). "Outcomes After Endoscopic Endonasal Resection of Craniopharyngiomas in the Pediatric Population". World Neurosurg. 108: 6–14. doi:10.1016/j.wneu.2017.08.058. PMID 28838874.
  5. Müller HL (June 2014). "Craniopharyngioma". Endocr. Rev. 35 (3): 513–43. doi:10.1210/er.2013-1115. PMID 24467716.

Template:WH Template:WS